Guggenheim Downgrades Albireo Pharma to Neutral

Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.

byBenzinga Newsdesk

January 11, 2023

1 minute read

Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.

Analyst Ratings

Expert Ratings For Honest Co

By Benzinga Insights

Today, 3:27 AM

Honest Co (NASDAQ:HNST) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago

HNST

3 Reasons The 2023 Stock Market Rally May Be ‘Another Bull Trap’

By Wayne Duggan

Today, 3:27 AM

The SPDR S&P 500 ETF Trust (NYSE: SPY) is up more than 6% year-to-date in 2023, but Tom Essaye, founder of Sevens Report Research, said Friday there are at least three warning signs that the rally could be yet another

SPY

Analyst Ratings

Where DuPont de Nemours Stands With Analysts

By Benzinga Insights

Today, 3:27 AM

Over the past 3 months, 7 analysts have published their opinion on DuPont de Nemours (NYSE:DD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

News

Daqo New Energy Announced it Began Pilot Production at New Phase 4B Polysilicon Production Facility

By Charles Gross

Today, 3:27 AM

Daqo New Energy Corp. (NYSE: DQ) ("Daqo New Energy", the "Company" or "we"), a leading manufacturer of high-purity polysilicon for the global solar PV industry, today announced that it had completed the construction ahead of schedule and begun pilot production at its new 35,000 MT Phase 4B polysilicon production facility.

Guggenheim Downgrades Albireo Pharma to Neutral

Related Posts

Expert Ratings For Honest Co

3 Reasons The 2023 Stock Market Rally May Be ‘Another Bull Trap’

Where DuPont de Nemours Stands With Analysts

Daqo New Energy Announced it Began Pilot Production at New Phase 4B Polysilicon Production Facility